DGAP-News: Celesio AG / Key word(s): Quarter Results
Celesio AG: New strategy is starting to show first results - Celesio
improves revenue and earnings in the first quarter of 2012
14.05.2012 / 07:00
---------------------------------------------------------------------
New strategy is starting to show first results - Celesio improves revenue
and earnings in the first quarter of 2012
* EBITDA above prior-year level at 139.9 million euro (plus 5.1 per cent)
* Operational Excellence Programme for the stabilisation of earnings is
beginning to take effect
* Sales process for Movianto, Pharmexx and the DocMorris mail-order pharmacy
initiated
Stuttgart, 14 May 2012. In the first quarter of 2012, Celesio, a leading
international trading company and provider of logistics and services in the
pharmaceutical and healthcare sector, achieved first successes in line with
its strategic realignment. Revenue increased by 2.5 per cent to 5.6 billion
euro, while operating earnings (EBITDA) climbed by 5.1 per cent in the first
three months of 2012 to 139.9 million euro, before one-off expenditures. The
measures initiated, and especially the Operational Excellence Programme, are
beginning to take effect.
'The first quarter of 2012 shows clearly that we are on the right track with
our new strategy. We have reached our targets and boosted revenue and
earnings compared to the prior-year period. We are extremely pleased with
this development,' Celesio CEO Markus Pinger points out. 'This year we will
build upon the strategic realignment, which we started in 2011. We consider
the current year 2012 to be a year of transition. This means: in 2012, we
mainly want to stabilise our earnings performance. And we will follow our
roadmap step by step. At the end of April, we bought the remaining shares in
Panpharma, one of the leading pharmaceutical wholesalers in Brazil. This
strengthens our leading market position in Brazil and allows us to better
participate in the future growth of the Brazilian market. All of our
strategic alignment activities in 2012 will provide the basis for profitable
growth.'
In the Patient und Consumer Solutions division, EBITDA before one-off
effects increased by 27.3 per cent to 62.1 million euro. At 47.4 million
euro, EBIT before one-off effects clearly exceeded the prior-year value by
36.1 per cent. The division's strong performance was driven by the good OTC
business in the UK and Norway as well as positive effects of the Operational
Excellence Programme in Sweden and the UK.
In the Pharmacy Solutions division, EBITDA came out to 102.4 million euro,
down 5.2 per cent compared to the prior-year level. The positive
developments in Germany and Austria were not enough to offset burdens in
France resulting from strong competition and regulatory intervention.
In line with the strategic realignment, Celesio decided to initiate a sales
process for a number of companies and activities that are no longer part of
the core business. After having thoroughly reviewed and analysed all
strategic options, the Management Board took the decision at the end of
March to sell Movianto and Pharmexx as well as the DocMorris mail-order
pharmacy. Since the decision has been made, these businesses are carried as
discontinued operations.
Earnings outlook
The Management Board confirms the earnings outlook for 2012 and continues to
expect EBITDA before one-off expenditures at least at the level of financial
year 2011.
Key figures Celesio Group
1st quarter 1st quarter
2011 2012
Revenue EUR m 5,504.1 5,642.8
EBITDA
adjusted 1) EUR m 133.1 139.9
EBIT
adjusted 1) EUR m 103.4 106.7
Profit before tax
adjusted 1) 2) EUR m 78.7 83.9
Earnings
adjusted 1) 2) EUR m 50.6 53.0
Earnings per share
undiluted
adjusted 1) 2) EUR 0.29 0.31
Change
on a
euro basis
in %
Revenue EUR m 2.5
EBITDA
adjusted 1) EUR m 5.1
EBIT
adjusted 1) EUR m 3.2
Profit before tax
adjusted 1) 2) EUR m 6.6
Earnings
adjusted 1) 2) EUR m 4.7
Earnings per share
undiluted
adjusted 1) 2) EUR 6.9
1) Adjusted for one-off effects, especially from the Operational Excellence
Programme (including tax effects)
2) Adjusted for special effects included in the financial result
Press contact
Dr Jens Schreiber, Celesio AG, +49 (0)711.5001-380
media@celesio.com
Rainer Berghausen, Celesio AG, +49 (0)711.5001-549
media@celesio.com
About the Celesio Group
Celesio is a leading international trade, logistics and service company
working in the pharmaceutical and healthcare sector that proactively and
preventatively ensures that patients receive optimum care and support. We
operate in 27 countries worldwide and employ around 46,000 people. With more
than 2,200 of our own and 4,500 partner and brand partner pharmacies, we
look after more than two million customers daily. We supply around 65,000
pharmacies and hospitals with up to 130,000 medications through our
approximately 140 branches.
End of Corporate News
---------------------------------------------------------------------
14.05.2012 Dissemination of a Corporate News, transmitted by DGAP - a
company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------
Language: English
Company: Celesio AG
Neckartalstr. 155
70376 Stuttgart
Germany
Phone: +49 (0)711 5001-735
Fax: +49 (0)711 5001-736
E-mail: investor@celesio.com
Internet: www.celesio.com
ISIN: DE000CLS1001
WKN: CLS100
Indices: MDAX
Listed: Regulierter Markt in Berlin, Düsseldorf, Frankfurt (Prime
Standard), München, Stuttgart; Freiverkehr in Hamburg,
Hannover; Terminbörse EUREX
End of News DGAP News-Service
---------------------------------------------------------------------
169584 14.05.2012
DGAP-News: Celesio AG: New strategy is starting to show first results - Celesio improves revenue and earnings in the first quarter of 2012
| Source: EQS Group AG